Faster Recovery.

Less Pain.

Through therapeutic vibration VibeTech is the leader in helping those in need of strength recover faster with less work.

FDA Listed Technology

Learn about VibeTech

INTRODUCING THE VIBETECH 3

VibeTech has taken what it learned from the treatment of thousands of patients and turned it into its smartest device yet, the VibeTech 3.

The VibeTech 3 is VibeTech’s answer to the call to reduce falls in the highest risk older adults. It activates the muscles throughout the legs using safe and effective, patient-specific (AutoDosing™) therapeutic vibration. Treatment is delivered through a footplate to a seated user. There is no transfer needed for wheelchair users. This portable device can be disinfected and brought to individual patient rooms or it can be placed in a rehab gym or other common space to boost strength and function while reducing pain in the lower extremities.

It is intended for both rehabilitative and restorative care purposes. Treatments with VibeTech’s technology are safe, effective, accessible, and reimbursable, and they have been shown to reduce falls, boost strength, elevate mood, and reduce pain in older adults with mobility impairments (as well as those living with Alzheimer's disease who are twice as likely to fall as other nursing home residents).

Unlike electrical stimulation, therapeutic vibration does not impart electricity into the body. Rather, it replicates minute mechanical signaling that occurs every time a step is taken as well as every time the muscles contract. When taking steps and performing physical activity is difficult or impossible due to physical or cognitive decline, the VibeTech 3 enables the user to rapidly progress, reversing the effects of dysmobility to reduce the risk of falls and fall-related injuries.

Pre-order today!

W H O I S V I B E T E C H

OVER 20,000 PATIENT TREATMENTS COMPLETE

The VibeTech family trusts our product can change your life, increase mobility, reduce falls, and get you back on your feet.

VibeTech brings safe, accessible physical therapy and occupational therapy to people with impaired physical mobility. The device can be used while the user is seated, with or without user effort.

VibeTech technology is patented and FDA registered. It is designed to address issues of individual patients, help therapists, nurses, and other staff with their work and make it easy for facilities, centers and hospitals to spread smiles along with financial and other benefits. Impaired physical mobility, pain and other neuromuscular conditions pose difficult problems in the lives of many and needs careful attention.

W H Y V I B E T E C H

OUR SOLUTIONS

100% passive therapy for individuals with extremely low

levels of weight bearing tolerance and range of motion.

Track progress using smart technology

To deliver suitable neuromuscular therapy and guide physical therapists through a progressive treatment plan on our accessible physical therapy and occupational therapy equipment, we provide step-by-step protocols in text, picture and video format. The videos also are included on the touch screen to make it easy for therapists to follow a plan and for administrators to document each case.

There are three phases of treatment protocols for neuromuscular therapy to improve impaired physical mobility, starting with 100% passive therapy for individuals with extremely low levels of weight bearing tolerance and range of motion. The therapist helps the individual to work to the next level of progression as therapy outcome goals are met and the individual has achieved an acceptable level of strength and mobility.

Learn about the VibeTech 3

Pain and arthritis

Neuromuscular therapy with the VibeTech Two activates the muscles, tendons, ligaments and bones in the lower body to mobilize joints to reduce pain and stiffness.

Our smart dosing technology can help individuals with osteoarthritis and other joint pain, leg pain and low back pain significantly reduce or eliminate pain.

Learn about The VibeTech 2

Atrophy, strength, and circulation

Loss of muscle and bone mass can be caused by aging, disease, disability, illness, injury, and surgery. The most common reason for atrophy to occur in the legs is disuse.

Learn about treatable conditions

See VibeTech featured on CBS Sunday Morning

V I B E T E C H A W A R D S

AWARDED MOST INNOVATIVE IN WISCONSIN 2017

Unleashing the potential of therapeutic vibration -delivering faster recovery with less pain.

VibeTech has been operating a research and demonstration site in Sheboygan, Wisconsin since the summer of 2018. In that time, we have had nearly 50 visitors comprised of healthy individuals, people with mobility impairments, people recovering from injury/surgery, individuals looking to build strength before surgery, people with neuropathy, people looking to reduce pain in their feet, legs, and low back, and more. We captured data from every user. Below are some highlights from this work.

Learn more

W H O V I B E T E C H H E L P S

WE SERVICE PATIENTS WITH MOBILITY ISSUES

We know our product can change your life, increase mobility, reduce falls, and get you back on your feet.

With the introduction of the new VibeTech 3 portable therapeutic vibration device to nursing homes, activities centers, assisted living facilities, group homes, memory care facilities and hospitals in communities throughout the United States, VibeTech is poised to offer training and assistance in demonstrating how to collaborate to provide the most effective fall reduction program available to people living with cognitive impairments and others who are at a heightened risk of falls throughout the continuum of care.

VIBETECH NEWS AND UPDATES

VIBETECH IN THE NEWS

CBS Sunday Morning

October 9, 2020

NASA-sponsored health technology lands in Sheboygan

PBS Milwaukee - Next Avenue Community Conversations

October 9, 2020

Next Avenue Community Conversations: Health Care at Home

VIBETECH POSTS & UPDATES

VibeTech earns Forward BIOLABS ICP Award

By Jeff Pederson • February 11, 2026

February 3, 2026 Forward BIOLABS has announced the first round of awardees for its Innovation to Commercialization Pipeline (ICP) program , a new initiative designed to help early-stage biohealth companies across Wisconsin move closer to market readiness. The ICP program provides targeted, non-dilutive support to startups working to translate scientific innovation into commercial products. The program is aimed at companies navigating early commercialization challenges, including regulatory strategy, intellectual property development, scale-up planning and investment readiness. Forward BIOLABS announced that 18 emerging biohealth companies were selected in the program’s inaugural round. Each company received between $25,000 and $75,000 in non-dilutive funding, with award amounts tailored to the specific commercialization needs of each business. The selected companies span a wide range of biohealth sectors, including medical devices, diagnostics, biomanufacturing, life sciences, pharmaceuticals and radiopharmaceuticals. Collectively, the awardees reflect both Wisconsin’s established strengths in imaging and healthcare technologies and growing momentum in highly investable areas such as AI-enabled platforms and radiopharmaceutical development. ICP Round 1 awardees Archeus Technologies (Madison) – Developing radiopharmaceutical therapies and imaging agents for oncology. Arkayli Biopharma (Madison) – Developing targeted precision drug delivery for pediatric rare skin and vascular diseases. Axio Biopharma (Madison) – Building an AI-ready biologics CDMO with a cross-site data ecosystem. AyrFlo Innovation Labs (Madison) – Developing a noninvasive wearable breathing sensor to detect post-surgical deterioration. Crainosure (Madison) – Developing a smartphone app to help primary care providers screen infants for head shape differences. Estrigenix Therapeutics ( Milwaukee) – Developing drugs to treat symptoms associated with menopause. ImgGyd (Middleton) – Developing hardware and software for image-guided placement of minimally invasive brain electrodes and catheters. Immuto Scientific (Madison) – Building an automated, high-throughput platform for protein characterization in cells and solutions. Kivi Bio (Kenosha) – Supporting early-stage and scaling biohealth companies lacking access to biomanufacturing equipment. Phoenix-Aid (Madison) – Developing advanced wound care dressings using patented nanocomposite materials. Refined Sciences (Madison) – Specializing in bioprocessing components and assemblies for the biopharmaceutical industry. Retham Technologies (Milwaukee) – Developing a diagnostic test for heparin-induced thrombocytopenia to reduce patient risk. Roddy Medical (Milwaukee) – Developing medical line securement technology focused on improving patient safety. Sonoptima (Milwaukee) – Developing a wearable, AI-enabled ultrasound technology for radiation therapy timing. Soul Mobility (Oconomowoc) – Building mobility products for users in the complex rehabilitation wheelchair market. Stem Pharm (Fitchburg) – Developing small-molecule therapies for neuroinflammatory diseases, including Alzheimer’s disease. Varizymes (Middleton) – Developing rapid point-of-care molecular diagnostic reagents. Vibetech Enterprises (Sheboygan) – Developing rehabilitation technology to improve physical mobility and safe exercise access. Funding for the ICP program is supported through state-matched Wisconsin Biohealth Tech Hub funding under 2023 WI Act 96. The program is one of five initiatives that make up the Wisconsin Biohealth Tech Hub, which aims to strengthen the state’s biohealth ecosystem and accelerate company growth statewide. Awardees were selected through a competitive review process by the ICP Award Committee, a group of volunteer industry leaders from across Wisconsin’s biohealth and investment communities. The committee was led by Jessica Martin Eckerly , CEO and co-founder of Forward BIOLABS , and Lisa Johnson , CEO of BioForward Wisconsin, and included Brad Garcia , director of strategy and operations at AbbVie ; Elizabeth Hagerman , chief innovation officer at UW Health and executive director of the Isthmus Project ; Jay Hill , retired vice president of advanced technology at GE Healthcare ; Jenni Le , principal at Venture Investors Health Fund ; Jill Enos , managing partner at TitletownTech ; Justin Krause , vice president of global operations coordination and integrations at Exact Sciences ; Laura Hilty , principal at HealthX Ventures ; Nicolas Paris , CEO of Gilson ; and Sarah Duellman , biotech industry strategy and growth lead at Promega . Forward BIOLABS said the committee evaluated applications based on commercialization readiness, proposed use of funds and potential impact on Wisconsin’s biohealth sector. Martin Eckerly said the selected companies represent a group that is not only working in emerging areas of biohealth but also nearing key moments of commercial impact. “The winners here really include companies that are at the cutting edge of industry. They are the next wave of technologies,” she said. Several of the awardees are approaching regulatory milestones, scale-up decisions or initial commercialization efforts, making the ICP awards a timely form of support rather than a general infusion of capital. She added that the cohort reflects a broader strength of Wisconsin’s innovation ecosystem, where companies tend to focus on execution and technical progress before seeking visibility. She noted the ICP program is designed to support companies that are already doing the work and need targeted resources to move forward, reinforcing Wisconsin’s reputation as a place where biohealth innovations are built and validated. A second round of ICP awards is planned for 2026.